Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 2/6/2019: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | * 2/6/2019: Initial approval for adult patients with [[Thrombotic thrombocytopenic purpura|acquired thrombotic thrombocytopenic purpura (aTTP)]], in combination with plasma exchange and immunosuppressive therapy. | ||
| + | ==History of changes in EMA indication== | ||
| + | *8/30/2018: Initial authorization | ||
== Patient Drug Information== | == Patient Drug Information== | ||
| Line 27: | Line 29: | ||
[[Category:Thrombotic thrombocytopenic purpura medications]] | [[Category:Thrombotic thrombocytopenic purpura medications]] | ||
| + | [[Category:EMA approved in 2019]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Revision as of 14:46, 1 January 2023
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
History of changes in EMA indication
- 8/30/2018: Initial authorization
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi